AI Score

Unlock

Summit Therapeutics Inc. (SMMT)

AI Score

Unlock

20.13

-0.56 (-2.71%)

At close: Mar 25, 2025, 3:59 PM

19.91

-1.11%

Pre-market: Mar 26, 2025, 04:32 AM EDT

-2.71% (1D)

Bid	19.54
Market Cap	14.85B
Revenue (ttm)	n/a
Net Income (ttm)	-225.92M
EPS (ttm)	-0.31
PE Ratio (ttm)	-64.94
Forward PE	-77.98
Analyst	Buy

Ask	20.23
Volume	1,369,600
Avg. Volume (20D)	2,426,903
Open	20.61
Previous Close	20.69
Day's Range	19.70 - 20.45
52-Week Range	2.10 - 33.89
Beta	-1.04

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, fo...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 5, 2015

Employees 159

Stock Exchange NASDAQ

Ticker Symbol SMMT

Website https://www.summittxinc.com

Full Company Profile

Analyst Forecast

According to 11 analyst ratings, the average rating for SMMT stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 58.97% from the latest price.

Stock Forecasts

Why Price Moved

2 days ago New

+4.76%

Summit Therapeutics shares are trading higher on p... Unlock content with Pro Subscription

2 weeks ago

+7.62%

Summit Therapeutics shares are trading higher after Evercore ISI Group initiated coverage on the stock with an Outperform rating and announced a price target of $30.

News

2 days ago · benzinga.com

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics

On Friday, Cantor Fitzgerald initiated coverage on Summit Therapeutics Inc. SMMT, citing shares as 67% undervalued.

3 days ago · fool.com

Is Summit Therapeutics a Millionaire Maker?

Multiple paths to immense wealth exist. A few lucky people win the lottery.

5 days ago · businesswire.com

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of...

6 days ago · fool.com

This Unstoppable Biotech Stock Just Became an Even Better Buy

Last year, Summit Therapeutics (SMMT -1.24%) was one of the stars of the biotech industry. The company's shares soared following a significant clinical win.

1 week ago · businesswire.com

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Offic...

1 week ago · fool.com

Why Summit Therapeutics Stock Was Winning This Week

A very bullish analyst move was the news generally responsible for Summit Therapeutics' (SMMT -3.62%) healthy mid-week stock price pop. That upward lift was largely holding as of Friday before market ...

1 week ago · fool.com

This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year

Summit Therapeutics (SMMT 7.62%) has been one of the hottest stocks to own over the past 12 months, with its valuation soaring 300% during that stretch. But things have slowed of late and since the st...